Biotech double antibody product BAT7104 obtained clinical trial approval

Recently, Biotech Biopharmaceutical Co.
, Ltd.
announced that it has received the "Clinical Trial Approval Notice" for the company's research product BAT7104 injection, which is intended to be used for the treatment of patients with advanced malignant tumors
.

 BAT7104 is a bispecific antibody against PD-L1 and CD47 developed by Biotech, which is intended to be developed for tumor treatment
.

On the one hand, BAT7104 activates macrophages to phagocytose tumor cells by blocking the CD47/SIRPα pathway; on the other hand, BAT7104 blocks the PD-L1/PD-1 pathway and relieves tumor cells from blocking the PD-L1/PD-1 pathway.
Inhibition of T cells realizes the combined anti-tumor effect of T cells and macrophages
.

Through the differential design of affinity, the targeting CD47 arm of BAT7104 has moderate affinity, reducing the potential for toxic side effects; at the same time, its targeting PD-L1 arm has high affinity, which can improve the tumor cell selectivity of antibodies and enhance targeting Tumor cell toxicity
.

 Biotech’s R&D layout is mainly concentrated in the oncology field.
According to its prospectus submitted, there are still 6 anti-biological drugs with unannounced targets in the preclinical pipeline
.

 Because double-antibody drugs have obvious advantages over monoclonal antibodies in terms of improving efficacy and reducing side effects, they have become a battleground for various pharmaceutical companies
.

Although there is no anti-PD-L1/CD47 bispecific antibody that has been approved for marketing in the world, many anti-PD-L1/CD47 bispecific antibodies are undergoing clinical trials in China
.

For example, the anti-CD47/PD-L1 bispecific antibody IBI322 independently developed by Innovent has now obtained IND approval from the National Medical Products Administration and the US FDA, and is actively preparing for clinical research around the world
.

In addition, SG12473, the first bi-antibody project of Shangjian Biologics, was approved by the National Food and Drug Administration and the US FDA for clinical research.
This is a bispecific antibody that targets both PD-L1 and CD47
.

In addition to the anti-PD-L1/CD47 bispecific antibodies that are undergoing clinical trials, there are also a number of PD-L1/CD47 bispecific antibodies that are in the preclinical development stage, which also illustrates the future market competition in this field It will be more intense
.

End Reference: [1]https:// The price of selected onlookers in the past is going to increase! Science publications revealed that high-salt diets may induce effective tumor immunity and anti-cancer exercises add new evidence: long-term exercise can create a cancer-suppressing environment in the body.
Safety accidents frequently occur, and clinical trials are once again stopped by the FDA.
, The "Squid Game" of the CAR-T circuit has officially started.
Why do hot writers get cancer? "Nature" sub-issues sequenced somatic cells, embryos, and sperm found that important genes, high-fat and high-sugar diet, make you fat and old? Nature publication: "Fasting" for 5 days a month can reverse obesity and reshape health medicine immunotherapy | biosimilars | vaccines | drug resistance | drug targets | healthy life | | Basic Research on Drug Side Effects/Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Diseases| Neurodegenerative Diseases| Intestinal Microbiology Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Biology Nano|3D printing|Gene detection|Single cell sequencing|Gene editing|Assisted reproduction|Artificial intelligence|Precision medicine policy Anticancer drugs|4+7 volume procurement|Consumables|Recording system|Registrant system|Health China|New basic medicine Contents| AI medical equipment| Telemedicine| Same stock market with different rights/capital IPO| Financing| Cooperation| Cooperation|